Sarizotan

Source: Wikipedia, the free encyclopedia.
Sarizotan
Clinical data
Pregnancy
category
  • N/A
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • Discontinued
Identifiers
  • 1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-([5-(4-fluorophenyl)pyridin-3-yl]methyl)methanamine
JSmol)
  • C1CC2=CC=CC=C2O[C@H]1CNCC3=CN=CC(=C3)C4=CC=C(C=C4)F

Sarizotan (EMD-128,130) is a

levodopa.[4][5][6][7]

In June 2006, the developer

Merck KGaA announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.[8][9]

See also

References

  1. S2CID 12943982
    .
  2. S2CID 9262233
    .
  3. S2CID 23379049
    .
  4. S2CID 24836560
    .
  5. S2CID 25419329
    .
  6. S2CID 46098045
    .
  7. PMID 19196540
    .
  8. ^ "Merck KGaA: Development of Sarizotan to treat Parkinson's patients will not be pursued". Ad Hoc News. 23 June 2006.
  9. ^ "Merck KGaA discontinues development of Parkinson drug Sarizotan UPDATE". Forbes. 23 June 2006.[dead link]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sarizotan&oldid=1191983650"